Quantcast
Last updated on April 18, 2014 at 11:16 EDT

Latest Ulcerative colitis Stories

2013-06-03 04:21:08

-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST- LONDON, June 3, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the second quarter and half year ended 31 March 2013. CORPORATE HIGHLIGHTS Initial public offering on the NASDAQ Global...

2013-05-15 16:28:06

First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction HORSHAM, Pa., May 15, 2013 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI(®) (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had...

2013-05-15 08:29:48

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has...

2013-05-02 08:39:04

For the Treatment of Severe Ulcerative Colitis, Remicade Holds a Strong Lead Over Humira, According to a New Report from BioTrends Research Group EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United...

2013-04-29 08:28:34

Gastroenterologists in the U.S. and EU5 Agree that Improved Maintenance of Remission is One of the Greatest Unmet Needs, According to a New Report from Decision Resources BURLINGTON, Mass., April 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies that offer improved effect on...

Primary Sclerosing Cholangitis Is A Unique Condition
2013-04-22 05:10:49

redOrbit Staff & Wire Reports - Your Universe Online Using DNA genotyping technology, researchers from the Wellcome Trust Sanger Institute have determined that primary sclerosing cholangitis (PSC), a rare autoimmune disease affecting the liver, is a unique condition and not a complication of inflammatory bowel disease (IBD). “Before our study, it was never quite clear whether PSC was a complication of IBD or a distinct disease in its own right. We have proven it to be a unique...

2013-04-15 23:00:43

Annual CCFA Spring Patient Education Day at Thomas Jefferson Hospital On Sunday, April 28, 2013. Philadelphia, PA (PRWEB) April 15, 2013 On Sunday, April 28, 2013, the Philadelphia/Delaware Valley Chapter of the Crohn´s & Colitis Foundation of America (CCFA) will proudly hold the Annual Spring Patient Education Day at Thomas Jefferson Hospital. This free program provides a supportive environment for patients, families and caregivers to learn about Crohn's disease and ulcerative...

2013-04-10 04:21:10

HEIDELBERG, Germany, April 10, 2013 /PRNewswire/ -- IND paves the way for the US element of a global Phase III development program with LT-02 in conjunction with European licensee Dr. Falk Pharma GmbH, whose pivotal study will start in Q4 2013 Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in...

2013-04-02 12:31:42

NEW YORK, April 2, 2013 /PRNewswire-iReach/ -- The Johns Hopkins University School of Medicine (JHUSOM) and DKBmed, LLC, have collaborated to create My Daily PACE, a mobile phone-based tool designed to help people with ulcerative colitis remember to take their medications and to track their symptoms. The tool is part of PACE UC: Persistence, Adherence, and Compliance Education in Ulcerative Colitis, an educational program created by JHUSOM and DKBmed. People with ulcerative colitis are...

2013-04-01 23:01:19

K´NEX to donate 10% of online sales to the CCFA during the month of April Hatfield, PA (PRWEB) April 01, 2013 K´NEX Brands, the only US construction toy company focused on Building Worlds Kids Love ®, is proud to announce that for the sixth year in a row it will donate a percentage of online sales to the Crohn´s & Colitis Foundation of America (CCFA), a non-profit, volunteer-driven organization dedicated to finding the cure for Crohn´s disease and ulcerative...